title: Fatal case of cryptogenic organizing pneumonia associated with everolimus.
abstract: Noninfectious pneumonitis (NIP) has been reported with everolimus; however, the majority of the reported cases were mild to moderate. We report a fatal case of cryptogenic organizing pneumonia (COP) in a 61-year-old man. About 4 weeks after starting everolimus, the patient was admitted to the hospital with complaints of a 1-week history of progressive dyspnea with exertion and cough. The chest radiograph showed bilateral multifocal dense opacities, and he was started on antibiotics. However, his respiratory status deteriorated, and he was subsequently intubated and transferred to the intensive care unit. Chest computed tomography showed bronchocentric consolidation associated with widespread bilateral fine reticular opacification. Video-assisted thoracoscopic lung biopsy showed noncaseating granulomatous inflammation and features of COP. All cultures were negative for bacterial, viral, and fungal infections. Despite discontinuing everolimus and initiating corticosteroids, the patient died of progressive respiratory failure secondary to COP.
authors.affiliation: Dr. Lama Nazer, King Hussein Cancer Center, Queen Rania St., Amman 11941, Jordan, T: (962-6)5300460, F: (962-6)5300468, inazer@khcc.jo.
authors.forename: Lama
authors.initials: L
authors.lastname: Nazer
authors.forename: Taghreed
authors.initials: T
authors.lastname: Alnajjar
authors.forename: Samer
authors.initials: S
authors.lastname: Salah
authors.forename: Jakub
authors.initials: J
authors.lastname: Khzouz
authors.forename: Nour
authors.initials: N
authors.lastname: Alfaqeer
authors.forename: Monther
authors.initials: M
authors.lastname: Qandeel
mesh_terms: D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000556:secondary; D018549:Cryptogenic Organizing Pneumonia / Q000139:chemically induced* / Q000000981:diagnostic imaging / Q000473:pathology; D000068338:Everolimus; D017809:Fatal Outcome; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011859:Radiography; D020123:Sirolimus / Q000009:adverse effects / Q000031:analogs & derivatives*
chemical_list: D007166:Immunosuppressive Agents; D000068338:Everolimus; D020123:Sirolimus
references.citation: Eur J Cancer. 2012 Feb;48(3):324-32
references.pmid: 21803569
references.citation: Ann Oncol. 2009 Oct;20(10):1674-81
references.pmid: 19549709
references.citation: Nihon Kokyuki Gakkai Zasshi. 2001 Mar;39(3):215-9
references.pmid: 11431918
references.citation: Ann Pharmacother. 2012 Mar;46(3):e7
references.pmid: 22333263
references.citation: Clin Pharmacol Ther. 1981 Aug;30(2):239-45
references.pmid: 7249508
references.citation: Lancet. 2008 Aug 9;372(9637):449-56
references.pmid: 18653228
references.citation: Eur Respir J. 1995 Jun;8(6):1018-20
references.pmid: 7589364
references.citation: J Thorac Oncol. 2009 Nov;4(11):1357-63
references.pmid: 19745764
references.citation: Am J Respir Crit Care Med. 2010 Aug 1;182(3):396-403
references.pmid: 20194812